secwatch / observer
8-K filed June 26, 2023, 7:59 PM ET ticker UNCY CIK 0001766140
other confidence high sentiment neutral materiality 0.20

Unicycive shareholders elect all 4 director nominees, approve reverse stock split and equity plan amendment

Unicycive Therapeutics, Inc.

item 5.07

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Unicycive Therapeutics, Inc. shareholders approved Election of four nominees for director to serve until the 2024 Annual Meeting of Stockholders or until their respective successors have been duly elected and qualified, or until such director's earlier resignation, removal or death. at the 2023-06-26 meeting.

Proposal
director election
Outcome
passed
Meeting
2023-06-26
Exact text from the filing
Proposal 1 . All of the four (4) nominees for director were elected to serve until the 2024 Annual Meeting of Stockholders or until their respective successors have been duly elected and qualified, or until such director’s earlier resignation, removal or death. The result of the votes to elect the four (4) directors was as follows: Directors For Withhold Abstain Broker Non Vote Dr. Shalabh Gupta 10,308,931 0 135,675 2,655,662 Dr. Sandeep Laumas 9,453,731 0 990,876 2,655,661 Dr. John Ryan 9,298,925 0 1,145,681 2,655,662 Dr. Gaurav Aggarwal 10,307,961 0 136,646 2,655,661
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Unicycive Therapeutics, Inc. shareholders approved Reverse Stock Split Proposal at the 2023-06-26 meeting.

Proposal
reverse split
Outcome
passed
Meeting
2023-06-26
Exact text from the filing
Proposal 4. The Reverse Stock Split Proposal was approved by the stockholders by the votes set forth in the table below: For Against Abstain Broker Non Vote 12,679,613 412,810 7,840 3
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Unicycive Therapeutics, Inc. shareholders approved Nasdaq 20% Issuance Proposal at the 2023-06-26 meeting.

Outcome
passed
Meeting
2023-06-26
Exact text from the filing
Proposal 3. The Nasdaq 20% Issuance Proposal was approved by the stockholders by the votes set forth in the table below: For Against Abstain Broker Non Vote 8,129,197 236,958 11,705 2,655,661
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Unicycive Therapeutics, Inc. shareholders approved Amendment and restatement of the 2021 Omnibus Equity Incentive Plan at the 2023-06-26 meeting.

Proposal
equity plan
Outcome
passed
Meeting
2023-06-26
Exact text from the filing
Proposal 5. The amendment and restatement of the 2021 Omnibus Equity Incentive Plan was approved by the stockholders by the votes set forth in the table below: For Against Abstain Broker Non Vote 9,474,374 959,587 10,645 2,655,662
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Unicycive Therapeutics, Inc. shareholders approved Ratification of appointment of Mayer Hoffman McCann P.C. as independent registered public accounting firm for fiscal year ending December 31, 2023. at the 2023-06-26 meeting.

Proposal
auditor ratification
Outcome
passed
Meeting
2023-06-26
Exact text from the filing
Proposal 2. The appointment of Mayer Hoffman McCann P.C. as the Company’s independent registered public accounting firm for its fiscal year ended December 31, 2023 was ratified and approved by the stockholders by the votes set forth in the table below: For Against Abstain Broker Non Vote 13,057,585 30,776 11,904 1
View on SEC.gov

1179 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Unicycive Therapeutics, Inc. filing history →

Source: SEC EDGAR
accession 0001213900-23-051702
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.